Compare RELL & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | CNTN |
|---|---|---|
| Founded | 1947 | 2017 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.3M | 184.2M |
| IPO Year | 2004 | 2022 |
| Metric | RELL | CNTN |
|---|---|---|
| Price | $14.18 | $3.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 135.0K | ★ 589.3K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $208,909,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.35 | $2.98 |
| 52 Week High | $15.34 | $5.27 |
| Indicator | RELL | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 43.02 |
| Support Level | $10.10 | $3.13 |
| Resistance Level | $15.04 | $3.63 |
| Average True Range (ATR) | 0.89 | 0.26 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 67.94 | 35.90 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.